Skip to main content
Top of the Page

Addressing Patent Enablement Issues Post Amgen

Addressing Patent Enablement Issues Post Amgen
The session will review the recent Amgen Supreme Court Decision, which found that Amgen's patent covering its cholesterol lowering drug Repatha invalid for lack of enablement. The claims of the patent are broadly directed to an antibody that binds certain epitopes on the PCSK9 enzyme. The session will involve analyzing the Supreme Court's rationale for lack of enablement and explore its impact on patenting strategies for life science discoveries more generally.
Discounted member price: 75.00
195.00
You could save: 61%
Back to Top
Contact
AUTM
712 H Street NE
Suite 1611
Washington DC 20002
+1.202.960.1800
[email protected]
Subscribe to the Newsletter

© All Rights Reserved.